Skip to content
The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C, Pinto C, Vieira J, Peixoto A, Pinto P, Pinheiro M, Santos C, Guerra J, Lisboa S, Santos R, Silva J, Leal C, Coimbra N, Lopes P, Ferreira M, Sousa AB, Teixeira MR.
Fam Cancer. 2020 Oct 14. doi: 10.1007/s10689-020-00212-2. Epub ahead of print.
Translating cancer risk prediction models into personalized cancer risk assessment tools: Stumbling blocks and strategies for success.
Waters EA, Taber JM, McQueen A, Housten AJ, Studts JL, Scherer LD.
Cancer Epidemiol Biomarkers Prev. 2020 Oct 12. doi: 10.1158/1055-9965.EPI-20-0861. Epub ahead of print.
Feedback of extended panel sequencing in 1,530 patients referred for suspicion of hereditary predisposition to adult cancers.
Cavaillé M, Uhrhammer N, Privat M, Ponelle-Chachuat F, Gay-Bellile M, Lepage M, Viala S, Bidet Y, Bignon YJ.
Clin Genet. 2020 Oct 12. doi: 10.1111/cge.13864. Epub ahead of print.
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
Michels J, Genestie C, Dunant A, Caron O, Lanoy E, Colomba E, Pommeret F, Rey A, Gouy S, Duvillard P, Le Teuff G, Larue C, Savoye AM, Lhommé C, Leary A, Morice P, Pautier P.
Gynecol Oncol. 2020 Oct 12:S0090-8258(20)33960-3. doi: 10.1016/j.ygyno.2020.09.050. Epub ahead of print.
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Haunschild CE, Tewari KS.
Gynecol Oncol. 2020 Oct 11:S0090-8258(20)33953-6. doi: 10.1016/j.ygyno.2020.09.043. Epub ahead of print.
Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model.
Greve V, Garner M, Odom K, Cooper SJ, East KM.
Patient Educ Couns. 2020 Oct 11:S0738-3991(20)305498. doi: 10.1016/j.pec.2020.10.014. Epub ahead of print.
Translating cancer risk prediction models into personalized cancer risk assessment tools: Stumbling blocks and strategies for success.
Waters EA, Taber JM, McQueen A, Housten AJ, Studts JL, Scherer LD.
Cancer Epidemiol Biomarkers Prev. 2020 Oct 12. doi: 10.1158/1055-9965.EPI-20-0861. Epub ahead of print.
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
Michels J, Genestie C, Dunant A, Caron O, Lanoy E, Colomba E, Pommeret F, Rey A, Gouy S, Duvillard P, Le Teuff G, Larue C, Savoye AM, Lhommé C, Leary A, Morice P, Pautier P.
Gynecol Oncol. 2020 Oct 12:S0090-8258(20)33960-3. doi: 10.1016/j.ygyno.2020.09.050. Epub ahead of print.
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Haunschild CE, Tewari KS.
Gynecol Oncol. 2020 Oct 11:S0090-8258(20)33953-6. doi: 10.1016/j.ygyno.2020.09.043. Epub ahead of print.
Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model.
Greve V, Garner M, Odom K, Cooper SJ, East KM.
Patient Educ Couns. 2020 Oct 11:S0738-3991(20)305498. doi: 10.1016/j.pec.2020.10.014. Epub ahead of print.
Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma.
Yadav S, Kasi PM, Bamlet WR, Ho TP, Polley EC, Hu C, Hart SN, Rabe KG, Boddicker NJ, Gnanaolivu RD, Lee KY, Lindstrom T, Petersen GM, Couch FJ, McWilliams RR.
Clin Cancer Res. 2020 Oct 7:clincanres.1788.2020. doi: 10.1158/1078-0432.CCR-20-1788. Epub ahead of print.
Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE, Nussbaum RL, Kurian AW, Nielsen SM, Das K, Michalski S, Yang S, Ngo N, Blanco A, Esplin ED.
JAMA Netw Open. 2020 Oct 1;3(10):e2019452. doi: 10.1001/jamanetworkopen.2020.19452.